742 related articles for article (PubMed ID: 18606548)
1. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis inhibition in the treatment of lung cancer.
Vokes E; Herbst R; Sandler A
Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
[TBL] [Abstract][Full Text] [Related]
3. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
Manegold C
Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
[TBL] [Abstract][Full Text] [Related]
4. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
de Gramont A; Van Cutsem E
Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835
[TBL] [Abstract][Full Text] [Related]
5. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Langer CJ; Natale RB
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab in non small cell lung cancer.
Sandler A
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4613-6. PubMed ID: 17671151
[TBL] [Abstract][Full Text] [Related]
7. Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung cancer.
Klamerus JF; Brahmer JR
Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S51-6. PubMed ID: 21884999
[TBL] [Abstract][Full Text] [Related]
8. New antiangiogenetic agents and non-small cell lung cancer.
Gridelli C; Rossi A; Maione P
Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002
[TBL] [Abstract][Full Text] [Related]
9. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
10. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer.
Sandler AB; Johnson DH; Herbst RS
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4258s-4262s. PubMed ID: 15217970
[TBL] [Abstract][Full Text] [Related]
11. The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments.
Gridelli C; Maione P; Rossi A; De Marinis F
Oncologist; 2007 Oct; 12(10):1183-93. PubMed ID: 17962612
[TBL] [Abstract][Full Text] [Related]
12. The potential of antiangiogenic therapy in non-small cell lung cancer.
Giaccone G
Clin Cancer Res; 2007 Apr; 13(7):1961-70. PubMed ID: 17404076
[TBL] [Abstract][Full Text] [Related]
13. Emerging antiangiogenic therapies for non-small-cell lung cancer.
Blakely C; Jahan T
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1607-18. PubMed ID: 21999134
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab in non-small-cell lung cancer: a review.
Planchard D
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1163-79. PubMed ID: 21916570
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic therapy in nonsmall cell lung cancer.
Gutierrez M; Giaccone G
Curr Opin Oncol; 2008 Mar; 20(2):176-82. PubMed ID: 18300767
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab for the treatment of advanced non-small-cell lung cancer.
Manegold C
Expert Rev Anticancer Ther; 2008 May; 8(5):689-99. PubMed ID: 18471042
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab plus platinum-based chemotherapy: in advanced non-small cell lung cancer.
Wagstaff AJ; Keam SJ; McCormack PL
BioDrugs; 2009; 23(3):187-96. PubMed ID: 19627170
[TBL] [Abstract][Full Text] [Related]
18. Targeting tumor neovasculature in non-small-cell lung cancer.
Pallis AG; Syrigos KN
Crit Rev Oncol Hematol; 2013 May; 86(2):130-42. PubMed ID: 23159217
[TBL] [Abstract][Full Text] [Related]
19. Beyond bevacizumab: antiangiogenic agents.
Rogosin S; Sandler AB
Clin Lung Cancer; 2012 Sep; 13(5):326-33. PubMed ID: 22297207
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]